One of the main challenges in early clinical research with RSV live-attenuated vaccines is to assess immunogenicity in healthy adults, as they will have preexisting levels of serum neutralizing antibodies that could prematurely neutralize the vaccine and underestimate its potential effect on the immune system. Therefore, we have recently assessed RSV-specific neutralizing antibodies in 290 healthy adult volunteers in order to help determine a cut-off serum titer that can be used as an eligibility criterion in future early phase RSV trials.
Read more in our recent publication.
